{"id":8039,"date":"2020-12-31T00:03:06","date_gmt":"2020-12-30T16:03:06","guid":{"rendered":"https:\/\/newsletter.sinica.edu.tw/en\/?p=8039"},"modified":"2024-03-13T09:18:15","modified_gmt":"2024-03-13T01:18:15","slug":"new-strategy-for-lung-cancer-treatments-chemotherapy-combined-with-tumor-immunotherapy","status":"publish","type":"post","link":"https:\/\/newsletter.sinica.edu.tw/en\/8039\/","title":{"rendered":"New Strategy for lung cancer treatments! Chemotherapy combined with tumor immunotherapy"},"content":{"rendered":"
Lung cancer is the leading cause of cancer death in Taiwan and the world, and its treatment has always been a topic of concern in the country. A research team composed of Drs. Pan-Chyr Yang (Academician of Academia Sinica), Shu-Ping Wang (Assistant Research Fellow) and Chia-Sing Lu (Postdoctoral Fellow) of the Institute of Biomedical Sciences, found that the chemotherapeutic agent \u201cPemetrexed\u201d can trigger the TS-ROS-NF-kB regulatory axis to activate the expression of PD-L1 in lung cancer cells, thereby creating a favorable tumor microenvironment for immunotherapy. The combined use of this chemotherapy and immunotherapy can become the first-line treatment for advanced lung cancer.<\/p>\n